Elderly patients with OAB benefit from mirabegron-solifenacin combination therapy

  • Mueller ER & al.
  • Neurourol Urodyn
  • 15 Jan 2019

  • curated by Craig Hicks
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Mirabegron (Myrbetriq) and solifenacin (Vesicare) combination therapy is a well‐tolerated and effective treatment for older patients with overactive bladder (OAB).

Why this matters

  • OAB symptoms increase with age.
  • This study is the first to evaluate long-term tolerability and effectiveness of mirabegron and solifenacin in combination in both young and old patients.

Study design

  • Researchers analyzed the health records of patients with symptoms of wet OAB who participated in the mirabegron-solifenacin trial (N=1794; age ≥65 years, 614; age ≥75 years, 168).
  • Patients were randomly assigned to receive a once‐daily combination of solifenacin succinate 5 mg and mirabegron 50 mg, solifenacin succinate 5 mg, or mirabegron 50 mg.
  • Funding: Astellas Pharma Europe B.V.

Key results

  • Researchers observed slightly higher incidences of treatment‐emergent adverse events (TEAEs) after combination therapy in all age groups.
  • The most common TEAE was dry mouth (
  • Combination therapy generally resulted in greater improvements in mean number of incontinence episodes per 24 hours, except for patients aged

Limitations

  • The ≥75 years subgroup had a small sample size.
  • A placebo group was not included because of treatment length.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit